Damora Therapeutics (DMRA) vs Harrow (HROW)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Damora Therapeutics (DMRA) has outperformed Harrow (HROW) over the past year, gaining 12.9% versus a loss of 26.9%. Over five years, HROW leads with a +209.6% price change compared with -76.3% for DMRA. Damora Therapeutics is the larger company by market cap ($1.27 billion vs $1.15 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DMRA | HROW |
|---|---|---|
| Share price | $20.55 | $30.72 |
| Market cap | $1.27B | $1.15B |
| 1-day change | +1.53% | +0.31% |
| YTD return | -12.04% | -37.51% |
| 1-year return | +12.95% | -26.92% |
| 5-year return | -76.33% | +209.61% |
| Forward P/E | — | 11.08 |
| EPS (TTM) | $-0.25 | $-0.99 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $38.33 | $54.85 |
| 52-week low | $4.95 | $28.54 |
| Distance from 52-week high | -46.38% | -44.00% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +128.18% | +111.62% |
| Average volume | 539.81K | 555.14K |
| Shares outstanding | 61.74M | 37.49M |
| Employees | 7 | 373 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DMRA has outperformed HROW by 39.9 percentage points over the past year.
About Damora Therapeutics
DMRA stock →Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
About Harrow
HROW stock →Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segments.
Health Care · Biotechnology: Pharmaceutical Preparations · 373 employees
DMRA vs HROW FAQ
Which is bigger, Damora Therapeutics or Harrow?
Damora Therapeutics (DMRA) is larger, with a market capitalization of $1.27B compared with $1.15B for Harrow (HROW).
Which stock has performed better over the past year, DMRA or HROW?
DMRA returned +12.95% over the past 12 months, compared with -26.92% for HROW (price return, excluding dividends). Past performance does not predict future results.
Are Damora Therapeutics and Harrow in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.